Clinical Trials Browser

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT04004221 2024-10-26

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Phase 2 Completed

113 enrolled 15 charts

Genitourinary

Locally Advanced or Metastatic Urothelial Bladder Cancer

NCT04952597 2024-10-26

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Phase 2 Completed

126 enrolled 19 charts

Thoracic

Limited Stage Small Cell Lung Cancer

NCT03432598 2024-10-23

Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer

Phase 2 Completed

54 enrolled

Thoracic

Lung Neoplasms

NCT03469557 2024-10-23

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

Phase 2 Completed

30 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Stomach Neoplasms

NCT05086627 2024-08-22

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Phase 2 Completed

118 enrolled

Gastrointestinal

Locally Advanced Rectal Cancer

NCT06232759 2024-06-10

TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

Phase 2 Completed

56 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05807542 2024-05-16

Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC

Phase 2 Completed

20 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT04310943 2024-03-06

Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma

Phase 2 Completed

24 enrolled

Thoracic

Adenocarcinoma of Lung

NCT06238752 2024-02-02

RENMIN-213

Phase 2 Completed

33 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT04507217 2023-05-25

Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC

Phase 2 Completed

36 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Clinical Trials

A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC

Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

FRONT-1

HESTIA

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors

PPIO-004-EC001

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

neoCHANCE-1

BRIGHT

neoCHANCE-2

SITISVEAL

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Tislelizumab in Addition to BACE in Patients with NSCLC

Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma

AdvanTIG-203

Study of BGB-A317 in Participants With Previously Treated Unresectable HCC

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer

BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC

Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma

RENMIN-213

Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC